Callahan Advisors LLC Has $8.56 Million Stock Position in STERIS plc (NYSE:STE)

Callahan Advisors LLC decreased its position in shares of STERIS plc (NYSE:STE) by 1.6% in the third quarter, Holdings Channel.com reports. The firm owned 35,283 shares of the medical equipment provider’s stock after selling 579 shares during the period. Callahan Advisors LLC’s holdings in STERIS were worth $8,557,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its position in STERIS by 13.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after purchasing an additional 778,613 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in STERIS by 7.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after buying an additional 120,616 shares in the last quarter. Sustainable Growth Advisers LP raised its holdings in STERIS by 23.5% during the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after buying an additional 282,387 shares in the last quarter. Impax Asset Management Group plc raised its holdings in STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after buying an additional 263,383 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in STERIS by 0.9% during the second quarter. Principal Financial Group Inc. now owns 1,017,888 shares of the medical equipment provider’s stock valued at $223,467,000 after buying an additional 8,601 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on STE shares. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and raised their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Wednesday, August 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.00.

STERIS Trading Up 0.7 %

STERIS stock opened at $227.44 on Wednesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. The business’s 50-day simple moving average is $233.36 and its 200-day simple moving average is $227.60. The firm has a market capitalization of $22.43 billion, a PE ratio of 56.44 and a beta of 0.85. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24.

STERIS (NYSE:STE) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same period in the previous year, the company posted $2.00 earnings per share. The company’s quarterly revenue was down .4% compared to the same quarter last year. Equities research analysts forecast that STERIS plc will post 9.02 earnings per share for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s payout ratio is 56.58%.

Insider Buying and Selling at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the sale, the director now directly owns 582 shares in the company, valued at $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.